Glenmark Pharmaceuticals Limited

Glenmark Generics Limited

Other

Glenmark Pharmaceuticals S.a.

Glenmark Life Sciences Limited

Sukumar Sinha

Shekhar Bhaskar Bhirud

Mubeen Ahmed Khan

Samir Naik

Sachin Srivastava

Nitin Sharad Chandra Pradhan

Mangesh Shivram Sawant

Nikhil Rasiklal Trivedi

Abraham Thomas

Suresh Mahadev Kadam

Sukeerthi Kumar

Sachin Baban Gavhane

Bipin Parsottam Kansagra

Sandeep Bandu Khandagale

Ranjeet Nair

Sharad R Gore

Nandkumar Gaikwad

Navin Ganesh Bhatt

Rajesh Kumar Dwivedi

Mubeen Ahmad Khan

Rajendra C Jagdhane

Jayant Prakashrao Patil

Shailendra Nilkanth Bhadane

Shailesh Shrirang Pawase

Dayaghan Gangadhar Patil

Girish Dixit

Vipin Kumar Pandey

Mahesh Khedekar

Ramjilal Yadav

Maloyesh Mathuresh Biswas

Bhavna Mishra

Mohammad Amjed Khan

Sachin Lad

Ramesh Santosh Badgujar

Dinesh Deore

Sandip Gadge

Nagan Nirmalan Kandasamy

Sachin Gavhane

Shailesh Pawase

Shailendra Bhadane

Rajesh Dwivedi

Navin Ganeshbhatt

Nikhil Rasiklaltrivedi

The present invention provides a process for preparation of deoxycholic acid or salt thereof; the process comprises the steps of reacting the compound of formula II to obtain a compound of formula III; the compound of formula III is converted to a compound of formula IV and the compound of formula IV is converted to deoxycholic acid. The present invention also provides a process for the purification of deoxycholic acid or salt thereof.

Process for the preparation of deoxycholic acid

The present invention relates to a process for the preparation of canagliflozin and intermediates thereof.

Process for preparation of canagliflozin

The present invention provides process for the preparation of ivacaftor and solvates thereof.

Process for the preparation of ivacaftor and solvates thereof

The present disclosure is directed to salts of N-{4-[2,4-difluoro-3-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl}dimethyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-5-yl)acetamide and process for the preparation thereof (formula II). 

Amides of 2-amino-4-arylthiazole compounds and their salts

An amorphous form of aprepitant and a process for its preparation is provided. Also provided are mixtures of polymorph Forms I and II of aprepitant and a process for the preparation thereof.

Amorphous and crystalline forms of aprepitant and processes for the preparation thereof

A solid crystalline form of 1-(2-[4-(6-methoxy-3,4-dihydronaphthalene-1-y) phenoxy]ethyl)pyrrolidine, and a preparing process thereof are provided. The aforesaid compound is a key intermediate in the synthesis of lasofoxifene. A process for preparing lasofoxifene, a process for purifying lasofoxifene tartrate, and a crystalline form of lasofoxifene tartrate are also provided.

Process for the preparation of lasofoxifene tartrate

The present invention generally relates to a process for the preparation of fosaprepitant dimeglumine intermediate and its use in the preparation of fosaprepitant dimeglumine; to a neutral form of fosaprepitant in a solid state and processes for the preparation thereof; and to a stable amorphous fosaprepitant dimeglumine, having a stability at temperatures of about 2&#xb0; C. to about 8&#xb0; C. and at a relative humidity below at least 60%; and a process for the preparation thereof.

Fosaprepitant dimeglumine intermediate, neutral fosaprepitant, and amorphous fosaprepitant dimeglumine and processes for their preparations

Processes for the purification of lercanidipine hydrochloride are provided which uses a binary system of an alcohol-containing solvent such as methanol and an aliphatic ester-containing solvent such as isopropyl acetate. Processes for the preparation of substantially amorphous lercanidipine hydrochloride are also provided. Also provided is lercanidipine hydrochloride substantially in polymorph form V.

Polymorphic form of lercanidipine hydrochloride and process for the preparation thereof

Growing community of inventors

Navi Mumbai, India

Sukumar Sinha